Novel therapies in the treatment of systemic lupus erythematosus

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1045-1053

  Dequet, C R ^a   Wallace, D J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Biological therapies; Immunomodulators; Systemic lupus erythematosus (SLE)

Indexed keywords

ABETIMUS; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTOVA; B7 ANTIGEN; BINDARIT; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; BROMOCRIPTINE; CLADRIBINE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOMODULATING AGENT; INTERLEUKIN 10 ANTIBODY; LEFLUNOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E10; MONOCLONAL ANTIBODY B7; MONOCLONAL ANTIBODY C5; MONOCLONAL ANTIBODY CD40; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; RITUXIMAB; TACROLIMUS; TAMOXIFEN; THALIDOMIDE; THIAMAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOPENIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERTENSION; IN VITRO STUDY; INFECTION; INHIBITION KINETICS; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; IMMUNE COMPLEX DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; VACCINATION;

EID: 0034882227     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response
2. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis
3. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes
4. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
5. IDEC Pharmaceuticals reports first quarter 2000 results
6. Treatment of murine lupus with CTLA-4Ig
7. Long term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
8. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule
9. Expression of CD28, CTLA4, CD80 and CD86 molecules in patients with autoimmune rheumatic diseases: Implications for immunotherapy
10. Updated phase 1 clinical results with an idiotypic vaccine (3E10) for SLE
11. Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with non active SLE with nephritis
12. Reduction in circulating dsDNA antibody titer after administration of LJP 394
13. SLE trial shows fewer renal flares in LJP 394 treated patients with high-affinity antibodies to LJP 394: 90-05 trial results
14. DNAse treatment of DNA-antiDNA immune complexes in SLE
15. DNAse treatment does not improve the survival of lupus prone NZB X NZW F1 mice
16. Recombinant human DNase I (rhDNase) in patients with lupus nephritis
17. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
18. Continuous administration of anti-interleukin 10 antibodies delays the onset of autoimmunity in NZB/W F1 mice
19. Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
20. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB X NZW F1 mouse model of systemic lupus erythematosus
21. Mycophenolate mofetil therapy in resistant or relapsing diffuse proliferative lupus nephritis following cyclophosphamide therapy
22. Mycophenolate mofetil in lupus nephritis: Clinical observations
23. Mycophenolate mofetil for systemic lupus erythematosus
24. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
25. Regulation of murine lymphokine production in vivo. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells
26. Low plasma androgens in women with active or quiescent systemic lupus erythematosus
27. Low plasma androgens in women with systemic lupus erythematosus
28. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study
29. GL701 (Prasterone, DHEA) improves systemic lupus erythematosus
30. GL701 (Prasterone, DHEA) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus
31. Improvement in bone mineral density in steroid-treated patients during treatment with GL701 (Prasterone, DHES)
32. Thalidomide: Current and potential clinical applications
33. Thalidomide exerts its inhibitory action on TNF alpha by enhancing mRNA degradation
34. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
35. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
36. Long term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus
37. Thalidomide for systemic lupus erythematosus
38. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
39. A pilot study of 2-Chlorodeoxyadenosine (2CdA) in the treatment of systemic lupus erythematosus associated glomerulonephritis
40. 2-Chlorodeoxyadenosine (2CdA) in patients with lupus nephritis
41. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: Association with IL-10 inhibition and increase in TNF-alpha levels
42. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice
43. Bindarit, a new potential therapeutic agent for lupus nephritis: A pilot study
44. Cyclosporine A in the treatment of sytemic lupus erythematosus: Results of an open clinical study
45. Long- term treatment of systemic lupus erythematosus with cyclosporine A
46. Cyclosporine for lupus membranous nephritis: Experience with ten patients and review of the literature
47. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporine A
48. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases
49. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-Ipr mice
50. Prolactin influences autoimmune disease activity in the female B/W mouse
51. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells
52. Bromocriptine in systemic lupus erythematosus, a double-blind, randomized placebo-controlled study
53. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine
54. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-1pr/1pr mice
55. Methimazole prevents induction of experimental systemic lupus erythematosus in mice
56. Spontaneous autoimmune disease in (NZB x NZW)F1 mice is ameliorated by treatment with methimazole
57. Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil
58. A pilot study of leflunomide in systemic lupus erythematosus (SLE)
59. Benefits of leflunomide (LEF) in systemic lupus erythematosus (SLE) outpatients
60. Phase I/II open-label, dose escalation trial of rituximab (rituxan) in patients with SLE